A team of researchers led by NYU Tandon School of Engineering’s Weiqiang Chen has developed a miniature device that could transform how blood cancer treatments are tested and tailored for patients.

The team’s microscope slide-sized “leukemia-on-a-chip” is the first laboratory device to successfully combine both the physical structure of bone marrow and a functioning human immune system, an advance that could dramatically accelerate new immunotherapy development.

This innovation comes at a particularly timely moment, as the FDA recently announced a plan to phase out animal testing requirements for monoclonal antibodies and other drugs, releasing a comprehensive roadmap for reducing animal testing in preclinical safety studies.

Researchers at UT Arlington have discovered a key enzyme, IDO1, that when blocked, helps immune cells regain their ability to properly process cholesterol—something that breaks down during inflammation. This breakthrough could offer a powerful new way to fight heart disease, diabetes, cancer, and more. By “turning off” this enzyme, the team restored cholesterol absorption in macrophages, potentially stopping disease at the source. Even more promising, they found a second enzyme, NOS, that makes things worse—raising hopes that targeting both could pave the way for transformative treatments for millions suffering from inflammation-driven conditions.

Scientists from Cincinnati Children’s and colleagues based in Japan report achieving a major step forward in organoid technology: producing liver tissue that grows its own internal blood vessels.

This significant advance could lead to new ways to help people living with hemophilia and other coagulation disorders while also taking another step closer to producing transplantable repair tissues for people with damaged livers.

The study, led by Takanori Takebe, MD, Ph.D., director for commercial innovation at the Cincinnati Children’s Center for Stem Cell and Organoid Research and Medicine (CuSTOM), was published in Nature Biomedical Engineering.

Why do some patients with precursors to bone marrow cancer never develop the disease? Researchers from the Department of Forensic Medicine at Aarhus University have discovered that some cells enter a dormant state and create a defense against cancer—a breakthrough that could lead to early treatment.

In a new study published in the journal Leukemia, researchers investigated multiple myeloma, a serious bone marrow cancer that arises in plasma cells.

Before the disease emerges, patients always have a precursor condition, either MGUS (monoclonal gammopathy of undetermined significance) or SMM (smoldering multiple myeloma). These conditions are not cancer themselves but are associated with an increased risk of developing bone marrow cancer—approximately 1% and 10% increased risk per year, respectively.